Table 2. Comparison of Costs of Providing Hospitalized Patients with Morphine Sulfate as Controlled Release Tablets (MS Contin) 60 mg 12 h, as a Solution 20 mg q 4 h p.o. or 60 mg/day by Continuous Subcutaneous Infusion [65]
![Table 2. Comparison of Costs of Providing Hospitalized Patients with Morphine Sulfate as Controlled Release Tablets (MS Contin) 60 mg 12 h, as a Solution 20 mg q 4 h p.o. or 60 mg/day by Continuous Subcutaneous Infusion [65]](https://asa2.silverchair-cdn.com/asa2/content_public/journal/anesthesiology/86/5/10.1097_00000542-199705000-00021/2/m_21tt2.png?Expires=1682572098&Signature=DqCJyoZXm1hfzRfIIVY4slpyjnnbh1c~30NtoKrdv5551YsvyjtXEea5AzZ7CUgwQoue4b6d9XwlJgx3zlQ4l2yl9bNlQBE4aUTsS7N922-xwFUg~33nct-H6kpJAbhG1DAmRHfC-VvfvGoAhEqiuHomkVL8EZ8hFKBQ80U21VM~tuh6za1npmb8gJRVKkHnVf5joD623OtzM3FSFw50x6qHO8MgTMfsiNen0iLO7tBf6YH47wjryXWEbzSc7FrLALauTLDwmuD1SFNOwCf0MYxnHbxOOncrX8i~rTedUgCtB7qBNPbQiPxcsYBhJf40GdvJZobiJDmiaKXMHhQccg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Table 2. Comparison of Costs of Providing Hospitalized Patients with Morphine Sulfate as Controlled Release Tablets (MS Contin) 60 mg 12 h, as a Solution 20 mg q 4 h p.o. or 60 mg/day by Continuous Subcutaneous Infusion [65]